This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
LYSYL OXIDASE INHIBITORS / Marais, Richard; Springer, Caroline; NICULESCU-DUVAZ, Dan; Miller, Natalie; Aljarah, Mohammed; Zambon, Alfonso; Leung, Leo; Smithen, Deborah; Brown, Michael; Tang, Haoran. - (2017 Oct 13).
LYSYL OXIDASE INHIBITORS
ZAMBON, Alfonso;
2017
Abstract
This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
| File | Dimensione | Formato | |
|---|---|---|---|
|
PAtetnt LOX.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
7.79 MB
Formato
Adobe PDF
|
7.79 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
